Fujifilm Diosynth Biotechnologies has agreed to reserve manufacturing capacity for a future Covid-19 therapy developed through the the COVID-19 Therapeutics Accelerator.

This programme was launched in March by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to remove barriers to drug development, and therefore speed up the therapeutic response to the novel coronavirus pandemic.

The manufacturing space reserved by Fujifilm Biotech in its facility in Hillerød, Denmark will be to support the supply of Covid-19 drugs to developing countries.

Fujifilm Biotech chief business officer Andy Fenny said: “Humanity is facing one of its most challenging times in recent history.

“Resolution calls for a global effort in collaboration between public, private and charitable entities.

“This partnership allows Fujifilm to deploy its leading technical expertise and significant production capacity to have a meaningful impact in the fight against this pandemic.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.